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Introduction: Brugada syndrome is a hereditary arrhythmia characterized by a specific electrocardiographic pattern
and an increased risk of sudden cardiac death, with an apparent absence of structural abnormalities or ischemic
heart disease. To date, mutations in the sodium channel, voltage-gated, type V, alpha subunit gene and glycerol-
3-phosphate dehydrogenase 1-like gene are estimated to account for approximately 28% of Brugada syndrome
probands.
Case presentation: We report the case of a 32-year-old mixed-race Brazilian man who is sodium channel, voltage-
gated, type V, alpha subunit gene and glycerol-3-phosphate dehydrogenase 1-like gene mutation-negative with a
type 1 Brugada electrocardiographic pattern and a history of high family mortality, including five sudden deaths
among relatives of whom four were first-degree relatives.
Conclusion: To the best of our knowledge, this is the first case of a patient who has Brugada syndrome and a
history of sudden death in four first-degree family members. This case report reinforces the evidence that genetic
studies are of limited use while determining risk but remain helpful for diagnosis, and that diagnosis via
electrocardiography is of great importance in preventing adverse events and stratifying risk. Although there are
several technologically advanced diagnostic tools, they might not be accessible in small towns and hospitals;
however, a basic diagnostic tool like electrocardiography is easily accessible.
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Brugada syndrome (BrS) is a hereditary arrhythmia char-
acterized by a specific electrocardiographic (ECG) pat-
tern and an increased risk of sudden cardiac death, with
an apparent absence of structural abnormalities or ische-
mic heart disease. BrS has a worldwide prevalence of 1
in 2000 individuals and an autosomal dominant inherit-
ance pattern with incomplete penetrance. The syndrome
generally affects young adult men, and the first clinical
symptoms normally occur at the age of approximately
40 years [1].* Correspondence: marcoscardio@hotmail.com
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reproduction in any medium, provided the orA definitive diagnosis of BrS is made when a type 1
Brugada ECG pattern (abbreviated as BrS-ECG+) is ob-
served in more than one right precordial lead (V1 to V3)
in the presence or absence of a sodium channel blocking
agent, together with one of the following conditions:
documented ventricular fibrillation, polymorphic ven-
tricular tachycardia, family history of sudden death at an
age younger than 45 years, presence of a BrS-ECG+
in family members, and inducibility of ventricular
arrhythmia with programmed electrical stimulation, syn-
cope, or nocturnal agonal respiration [2].
BrS is a disease with a strong genetic basis. Mutations
in the sodium channel, voltage-gated, type V, alpha sub-
unit (SCN5A) gene leading to a loss of function of the
cardiac sodium channel by different mechanisms is the
most common genotype found among patients with BrS.
In addition to SCN5A alterations, mutations in thetd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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gene cause abnormal trafficking of the cardiac sodium
channel to the cell surface and a reduction of approxi-
mately 50% of the inward sodium current. To date, mu-
tations in the SCN5A and GPD1L genes are estimated to
account for approximately 18% to 30% and 11% to 12% of
BrS probands, respectively; the prevalence of variants in
other disease-related genes (such as CACNA1C, CACNB2,
SCN1B, KCNE3, SCN3B, and HCN4) is yet unknown [3].
We report the case of a patient who is SCN5A and
GPD1L mutation-negative BrS-ECG+ and who has a his-
tory of high family mortality, including five sudden
deaths among relatives of whom four were first-degree
relatives. To the best of our knowledge, this is the first
case report of a patient who has BrS with a history of
sudden death in four first-degree family members.
Case presentation
A 32-year-old mixed-race Brazilian man presented at
our clinic with worry and fear of dying, given the occur-
rence of five sudden deaths in his family (Figure 1). The
patient (A) reported that his grandmother (F), his father
(E), and three of his six brothers (B, C, and D) had sud-
denly died in their sleep at the age of 35 years, 50 years,
3 months, 36 years, and 38 years, respectively.
In the evaluation of the patient and his brothers (G, H,
and I), underlying structural heart disease was ruled out
by results of echocardiography, chest roentgenogram,
and exercise tests. In addition, acute ischemia and meta-
bolic or electrolyte disturbances were ruled out by
laboratory test results. However, the patient’s ECG result
revealed spontaneous ST segment elevation in the right
V1, V2, and V3 precordial leads, indicating a diagnosisFigure 1 Family pedigree. The squares represent males and the circles re
parenthesis. The proband with the Brugada syndrome phenotype (type 1 Bof BrS (Figure 2), whereas his brothers (G, H, and I)
presented normal spontaneous ECG results. The pa-
tient’s brothers refused to undergo an electrophysio-
logical study with programmed ventricular stimulation;
hence, it is possible that we have underestimated the fre-
quency of BrS within the family.
On the basis of the patient’s ECG pattern and the
knowledge of sudden death in five family members, risk
stratification was performed, and according to the rec-
ommendation of the Brazilian Society of Cardiology
guidelines regarding implantable electronic cardiac de-
vices, an implantable cardioverter-defibrillator (ICD) was
implanted [4]. During the 4-year follow-up period, the
patient remained asymptomatic. Informed consent was
obtained for mutation analysis of coding regions and
splice junctions of the SCN5A and GPD1L genes.
Genomic deoxyribonucleic acid (DNA) was extracted
from the patient’s peripheral blood leukocytes using
standard protocols. The entire coding region and intron–
exon boundaries of both genes were amplified by polymer-
ase chain reaction, using intronic primers designed by our
group from the genomic sequences of SCN5A (28 exons,
accession number NG_008934.1) and GPD1L (8 exons,
accession number NG_023375.1; Table 1), followed by
bidirectional sequencing of amplicons using the BigDyeW
Terminator v.3.1 Cycle Sequencing Kit (Applied Bio-
systems, Forster City, CA, USA).
We were unable to identify any causative mutation in
the coding regions and intron–exon boundaries of the
SCN5A and GPD1L genes. However, we identified four
commonly known polymorphisms that comprised two
synonymous (SCN5A D1819D and GPD1L D136D), one
nonsynonymous (SCN5A H558R), and one splicingpresent females. Ages and age at death and/or event are in
rugada electrocardiographic pattern) is indicated by an arrowhead.
Figure 2 Type 1 Brugada electrocardiographic pattern. Electrocardiograms showing V1, V2, and V3 leads at the patient’s initial consultation.
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(IVS9-3C>A). All of these polymorphisms are heterozy-
gous nucleotide changes (Figure 3).
Discussion
BrS is a disease characterized by sudden cardiac death,
typically occurring during sleep, in relatively young indi-
viduals. However, BrS has also been demonstrated in
children and infants as young as 2 days and may serve
as a pathogenic basis for some cases of sudden infant
death syndrome. Therefore, ECG diagnosis and adequate
clinical management of patients are of fundamental im-
portance for the prevention of catastrophic events and
risk stratification [5].
We present a clinical case of a patient who is
mutation-negative BrS-ECG+ and who has a family his-
tory of high mortality, including five sudden deaths
among relatives of whom four were first-degree relatives.
The patient reported that his grandmother, father, and
three of his six brothers had died suddenly in their sleep
at the age of 35 years, 50 years, 3 months, 36 years, and
38 years, respectively. To the best of our knowledge, this
is the first case report of a patient who has BrS with a
history of sudden death in four first-degree family mem-
bers. Studies reporting sudden deaths of one first-degree
relative of patients with BrS are common; however, the
number of reports of sudden deaths of first-degree rela-
tives within a family decreases with the increase in num-
ber of sudden deaths within a family. García-Castro
et al. [6], for example, reported the case of a 40-year-old
man who was BrS-ECG+ whose mother and a son had
died suddenly at 52 and 20 years of age, respectively.
The SCN5A coding region and intron–exon boundaries
sequencing revealed that this patient harbored an in-
tronic mutation (IVS18-1G>A) that would affect ribo-
nucleic acid (RNA) processing, eliminating exon 19 of
the messenger RNA (mRNA) [6].
An ICD was implanted in our patient, and during the
four years of follow-up, no arrhythmic event was regis-
tered. In a large meta-analysis involving 1545 BrS
patients, Gehi et al. [7] reported that the risk of an event
was increased (p<0.001) among patients with a history
of syncope or sudden cardiac death during the follow-upperiod (relative risk, 3.24; 95% confidence interval [CI],
2.13 to 4.93). However, the risk of combined events
during the follow-up period was higher in men who
exhibited a spontaneous BrS-ECG+ than in those with a
drug-induced BrS-ECG+ (4.65- and 3.47-fold, respect-
ively). Moreover, 62% patients who recovered from an
aborted sudden death event have the risk of a new
arrhythmic event in the following 54 months, justifying
the need for an ICD in these patients, irrespective of the
presence of other risk factors [2].
Whereas the prevalence of GPD1L mutations is esti-
mated to be 11% to 12%, SCN5A mutations are found in
18% to 30% of BrS patients, and these variations cur-
rently represent the most common BrS genotype [3]. To
date, approximately 300 mutations in the SCN5A gene
have been described in association with BrS. Six other
genes (CACNA1C, CACNB2, SCN1B, KCNE3, SCN3B,
and HCN4) have been associated with BrS, but the
prevalence of variants in these genes is yet unknown [8].
To investigate the association between the occurrence
of a BrS-ECG+ and carriership of a SCN5A mutation,
Probst et al. [9] studied 13 families with a BrS-ECG+ in
whom at least five family members carried the familial
SCN5A mutation. However, a BrS-ECG+ was only found
in 18% of the mutation carriers at baseline and in 61%
after drug testing. Conversely, eight individuals had a
BrS-ECG+ but did not carry the familial mutation.
Regarding GPD1L, Makiyama et al. [10] performed an
extensive screening for the prevalence of GPD1L muta-
tions in 80 probands with BrS. However, only one syn-
onymous mutation (A155A) and one intronic variant
(48-30T>C), which were not present in 220 control
alleles, were identified. However, the existence of family
members who were carriers of the mutation but re-
mained asymptomatic and had a normal ECG result in-
dicates that genetic studies are of limited usefulness for
determining risk but remain helpful for diagnosis [6].
As pointed out by Probst et al. [9], there is no reason to
believe that the subjects with BrS-ECG+, who do not carry
the familial gene mutation, have no true BrS, especially
when these patients present spontaneous BrS-ECG+ with-
out other clinical abnormalities to explain the ECG aspect
of BrS, as observed in the patient presented in this report.
Table 1 Intron primers used to amplify the SCN5A and GPD1L exons





2 GAA TCA GGC CCA TTG TCT GTG (21) GAG TTG CAC AGA AGG GTA GGC (21) 400 59
3 CAC AGT CCA AGG GCT CTG AG (20) GAA TCA GCG CTA CTC TCA CTC C (22) 315 59
4 ATG CTG CTC AGC TTT CCT TG (20) GGC AAA AGA GGG TAG AAG CTG (21) 282 57
5 ACG TAA GGA ACC TGG AGA ACC (21) GCA AGG CAT AGC ACA GCA TAG (21) 236 57
61 and 72 GGT GGT TCT GCT TTG TAA TTC C (22) CCC AGG CAT ATC CCT CTA GC (20) 415 57
8 CCG TGC TTG TTC TTG CCT TC (20) GTC TGT CCT CTG TCT GGG TCT C (22) 399 59
9 CCC TCA CCA GCA TGA TGT TTC (21) CCT GGC AGG TAA GGG AGA CAA (21) 231 59
10 GAC GGC ATG GAA CAA AGT CTC (21) CCC ACA CTT GCT GTC CCT TG (20) 213 59
11 CCA GTG AGG GTG ACC TCT GC (20) CAG TCA GGT GAG GGC TTA GAG G (22) 281 61
12 GCT GCA CAA AGT CTC AAT GAT G (22) CCA CCC TGG AAA AGC TAG AAC (21) 267 57
13 GAA GAG CAC ATG TCA TGG TCG TG (23) CAG ACC TGC TGT GGT GCC TG (20) 456 61
14 GCT GAC GCA AAT CTC CTG AT (20) GCT TAA ATG ACC TGG GGT TG (20) 187 57
15 CTA ACT CAT TGG CTG TCC CC (20) CTT ACC CAT GAA GGC TGT GC (20) 347 57
16 GCC AGG GAG TCT TTC CAT CC (20) GTG ATG ACC TCA GAT TGG GTT G (22) 296 59
17 CTT CAC AAG GTC CCC TCC TC (20) TGG GTA GAT GGA TTG ATA GAA GG (23) 488 57
18 GGA CTG GAT GGC TTG GCA TG (20) GCT CTG GGC CCT GTA TAT GTA GG (23) 553 59
19 GCA TGG GCA GGG TCT GAA AC (20) GCT TCA GGG ACA AAG GCA TG (20) 280 59
20 GCT ACT CAG CCC ACA CTC ACA C (22) CTC TGG GTG GAA CTG AGG CTA G (22) 224 61
21 CAT TAG ATG TGG GCA TTC ACA G (22) CCA GCT GGA GAC CTC CTT TC (20) 294 57
22 GCT TCA TGT CCA CCT TGT CTG (21) CAA TGG GTT TCT CCT TCC TG (20) 252 57
23 GCC TAC TGT CTG TCC CCA AC (20) GGC CAT AGG ACA TCA GAA GC (20) 295 59
24 GGT CTT GAA AAG GGC ATG TG (20) CCA TTG GGA GGA AGG AAG TC (20) 386 57
25 GCT TCT GGC TTC ATC TGT CC (20) CAG ACA CTG ATT CCC TGG TG (20) 228 57
26 CCA GCC TGT CTG ATC TCC CTG (21) CCA ACA GGG AAG GTG AGA TGG (21) 283 61
27 CAG AAT GAG GTT GGT GCC TTC (21) CTG GGC TGA AAG ACT GTG AAG (21) 246 57
28 CCT GCT GAG CAC TTT CCA TTT G (22) GGT TGT ACA TGG CAT TCA GCA G (22) 396 57
29.13 GCC ACC AGT AGC CAC AGT CTC (21) GGC CTC TGG GTC AAA TTT CTC (21) 638 57
29.2 GTG CCT CTT CCA GAT CAC CAC (21) GAT AAC CAT GGC CGA CAC CTC (21) 619 57
29.3 CCT GAG TGA GGA CGA CTT CGA (21) GGC TGC TTT TCA GTG TGT CCT (21) 736 57
GPD1L
1 ACG GTC CAG GCG GCT ACA TT (20) GCT TCT GTG CGC TCA GTA ACG (21) 364 57
2 CTC TCC CGC CCA AGT GAG TT (20) CCA AGT GCT GCT CAG CCA AG (20) 297 57
3 CCT TGT GGA CAG GCA AGG TT (20) CAA TGT CTA GCC CTG GGC AG (20) 240 57
4 TCC CAT GCC TCT TTG ATT TG (20) ACA TCA AAT GTC CAG ACT CCT GG (23) 243 57
5 GGC TGT TAT TAA TAT CCT TGT TGT C (25) CAC AGA GCC CAT TCT TGA GGA (21) 236 57
6 GCA TCT GGG CTT TGT CAT CT (20) CCA AGC CAG GAG TCT CAA GT (20) 322 53
7 CAG CAT AGC AAG ACC CAT TCT (21) GGC TGG AAG TCC TGA GAA TAG (21) 299 53
8 CTG AGG TAA ATC CAG TGG CC (20) CAT CAT GTT GCC AAG TCC TG (20) 238 53
1Exon 6 of SCN5A is only present in transcript variant 3, which is represented by the reference sequence NG_008934.1. 2Alternate designation 6, numbering
commonly used in the literature. The same reasoning applies to the remaining exons (8 to 29). 3Several pairs of primers were synthesized to polymerase chain
reaction-amplify exon SCN5A 29 owing to its large sizes.
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Figure 3 Deoxyribonucleic acid sequencing analysis results. SCN5A (A) exon 10 IVS9-3C>A polymorphism, (B) exon 12 H558R, (C) exon 28
D1819D, and (D) GPD1L exon 4 D136D. All of the variations were heterozygous nucleotide changes in common polymorphic sites. A, adenine; C,
cytosine; T, thymine; G, guanine.
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tions in SCN5A and GPD1L might not be sufficient to
cause BrS but could act like a revelatory factor such as a
sodium channel blocker challenge.
Because of its location close to the intron 9–exon 10
boundary, IVS9-3C>A could be directly functionally
relevant because it could potentially induce alternative
splicing. However, IVS9-3C>A and two synonymous
common polymorphisms (SCN5A D1819D and GPD1L
D136D) found in our patient have already been reported
as polymorphisms without functional effects on the so-
dium channel [10].
The nonsynonymous SCN5A H558R polymorphism is
present in 20.4% to 32% of Caucasians, 29% of people of
African descent, and 10.4% of the Chinese population [11].
This polymorphism seems to be a genetic modulator of BrS
among carriers of a SCN5A mutation, in whom the pres-
ence of the less common allele G improves the ECG char-
acteristics and clinical phenotype [12]. In the present study,
we performed genomic sequencing of the entire coding re-
gions and intron–exon boundaries of the SCN5A and
GPD1L genes; however, we are not able to exclude the pos-
sibility of a mutation in the promoter regions of these
genes, which may decrease the RNA transcription rate, or a
mutation in its intronic regions, which may result in an al-
ternative splice site that competes with the normal splice
sites during mRNA processing. Besides, all the genes
known to be involved in the occurrence of the BrS have not
been sequenced. Therefore, it is also possible that other
gene mutations are responsible for the family history of
high mortality observed in our case.Conclusion
In conclusion, we report a high mortality rate in the
family of a patient who is mutation-negative BrS-ECG+;
the patient’s family has a history of sudden deaths during
sleep. This reinforced the hypothesis that increased vagal
tone increases the incidence of ventricular fibrillation.
This case report reinforces the evidence that genetic
studies are of limited use while determining risk but re-
main helpful for diagnosis, and that diagnosis via ECG is
of great importance in preventing adverse events and
stratifying risk. Although there are several technologic-
ally advanced diagnostic tools, they might not be access-
ible in small towns and hospitals; however, a basic
diagnostic tool like ECG is easily accessible. Given the
possibility of sudden cardiac death from BrS, the medical
community must provide information about BrS to
emergency physicians, as well as to clinicians and cardi-
ologists, indicating the need to be aware of all possible
diagnoses, irrespective of how unusual they may seem.
Consent
Written informed consent was obtained from the patient
for publication of this case report and accompanying im-
ages. A copy of the written consent is available for re-
view by the Editor-in-Chief of this journal.
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